Luvent LC is a combination of montelukast sodium and levocetirizine.
Montelukast sodium is a lukoterine receptor antagonist used for the treatment of asthma and related symptoms. It produces its action by blocking the action of leukoterine D4 and cysteinyl leukoterine receptors in lungs or bronchial tubes by binding to it.
Levocetrizine is a third generation non-sedative anti-histamine. Levocetirizine is an active R-enantiomer of cetrizine. It mainly causes blocking of histamine receptors and prevents the release of allergy chemicals released.
Treating allergic symptoms
Watery eyes, runny nose, itching eyes/nose, sneezing and itching
Once daily in the evening
It produces its action by selectively antagonizes leukoterine D4 (LTD4) at cysteinyl leukoterine receptor which is present in the body. By inhibiting the actions of CysLT1, it prevents the airway edema, smooth muscle contraction and enhanced secretion of viscous and thick fluid.
It competes with histamine for binding at H1 receptor on the effectors cell surface which causes the suppression histaminic edema and pruritus. The low incidence of sedation is because the reduced penetration of cetirizine into CNS.
After oral administration it gets rapidly absorbed with 64% of the bioavailability.
Nearly about 64% of the drug is absorbed after oral administration with 99% of the drug bound to plasma protein. The drug follows hepatic metabolism.
The drug is excreted through bile with elimination half life of 2.7-5.5 hrs. The clearance rate is 45mL/min in adults.
It is well absorbed in the body with mean peak plasma concentration (Cmax) of 114ng/mL at a time (Tmax) of 2.2 hours
It is well distributed in the body with 93% plasma protein binding. Vd is 0.41kg
The plasma half life is 7.9 ± 1.9 hours; total body clearance is 0.63 ml/min/kg
Prolong use can cause severe renal failure
Enlarged Prostate with Urination Problems
Hemodialysis with High-Flux Membrane
Allergic to either of the ingredient present in the formulation
Churg – Strauss syndrome.